Export Publications

Exporter les publications affichées :
Nombre de documents


Patrizia Giannoni

Article dans une revue14 documents

  • Kévin Baranger, Patrizia Giannoni, Stéphane Girard, Sarah Girot, Florence Gaven, et al.. Chronic treatments with a 5-HT4 receptor agonist decrease amyloid pathology in the entorhinal cortex and learning and memory deficits in the 5xFAD mouse model of Alzheimer's disease. Neuropharmacology, Elsevier, 2017, 126, pp.128-141. 〈10.1016/j.neuropharm.2017.08.031〉. 〈hal-01799428〉
  • Farron Mcintee, Patrizia Giannoni, Steven Blais, George Sommer, Thomas Neubert, et al.. In vivo Differential Brain Clearance and Catabolism of Monomeric and Oligomeric Alzheimer's Aβ protein. Frontiers in Aging Neuroscience, Frontiers, 2016, 8, 〈10.3389/fnagi.2016.00223〉. 〈hal-01705732〉
  • Patrizia Giannoni, Margarita Arango-Lievano, Ines Das Neves, Marie-Claude ă Rousset, Kévin Baranger, et al.. Cerebrovascular pathology during the progression of experimental ă Alzheimer's disease. Neurobiology of Disease, Elsevier, 2016, 88, pp.107-117. 〈10.1016/j.nbd.2016.01.001〉. 〈hal-01477817〉
  • Margarita Arango-Lievano, Patrizia Giannoni, Sylvie Claeysen, Nicola Marchi. Longitudinal in vivo imaging of the cerebrovasculature: relevance to CNS diseases. Journal of visualized experiments : JoVE, JoVE, 2016. 〈hal-01792491〉
  • Christophe Rochais, Cédric Lecoutey, Florence Gaven, Patrizia Giannoni, Katia Hamidouche, et al.. Novel milti-target directed ligands (MTDLs) with acetylcholinesterase (AChE) inhibitory and serotonergic subtype 4 receptor (5-HT4R) agonist activities as potential agents against Alzheimer's disease: the design of donecopride.. Journal of Medicinal Chemistry, American Chemical Society, 2015. 〈hal-01792475〉
  • Sylvie Claeysen, Joël Bockaert, Patrizia Giannoni. Serotonin: a new hope in Alzheimer's disease?. ACS Chemical Neuroscience, American Chemical Society (ACS), 2015. 〈hal-01792388〉
  • Cédric Lecoutey, Damien Hedou, Thomas Freret, Patrizia Giannoni, Florence Gaven, et al.. Design of donecopride, a dual serotonin subtype 4 receptor agonist/acetylcholinesterase inhibitor withpotential interest for Alzheimer's disease treatment.. Proceedin, 2014, 111 (36), pp.3825-3830. 〈hal-01064797〉
  • Cédric Lecoutey, Damien Hedou, Thomas Freret, Patrizia Giannoni, Florence Gaven, et al.. The design of donecopride, a dual 5-HT4R agonist/AChE inhibitor with potential interest for AD treatment. Proceedings of the National Academy of Sciences of the United States of America , National Academy of Sciences, 2014. 〈hal-01800439〉
  • Patrizia Giannoni, Florence Gaven, Dimitri De Bundel, Kevin Baranger, Evelyne Marchetti-Gauthier, et al.. Early administration of RS 67333, a specific 5-HT4 receptor agonist, prevents amyloidogenesis and behavioral deficits in the 5XFAD mouse model of Alzheimer’s disease. Frontiers in Aging Neuroscience, Frontiers, 2013, 5, 〈10.3389/fnagi.2013.00096〉. 〈hal-01703910〉
  • Sylvie Claeysen, Patrizia Giannoni. Serotonin type 4 receptor dimers. Methods in Cell Biology, Elsevier, 2013. 〈hal-01792387〉
  • Patrizia Giannoni. Alzheimer culprits: cellular crossroads and interplay. Cellular Signalling, Elsevier, 2012. 〈hal-01792371〉
  • Patrizio Blandina, Leonardo Munari, Patrizia Giannoni, Chiara Mariottini, Maria Passani. HISTAMINE NEURONAL SYSTEM AS THERAPEUTIC TARGET FOR THE TREATMENT OF COGNITIVE DISORDERS. Future Neurology, Future Medicine, 2010. 〈hal-01793879〉
  • Maria Beatrice Passani, Corrado Bucherelli, Elisabetta Baldi, Patrizio Blandina, Patrizia Giannoni. Histamine in the brain: Beyond sleep and memory. Biochemical Pharmacology, Elsevier, 2007, 73 (8), pp.1113 - 1122. 〈10.1016/j.bcp.2006.12.002〉. 〈hal-01762502〉
  • Gabriele Cenni, Patrizio Blandina, Ken Mackie, Daniele Nosi, Lucia Formigli, et al.. Differential effect of cannabinoid agonists and endocannabinoids on histamine release from distinct regions of the rat brain. European Journal of Neuroscience, Wiley, 2006, 24 (6), pp.1633 - 1644. 〈10.1111/j.1460-9568.2006.05046.x〉. 〈hal-01764807〉